PRQR
ProQR Therapeutics BV
1.60$
-1.2%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -548.0% | -162.1% | -340.0% | -99.2% | -147.2% | -217.0% | -349.6% | -298.7% | -419.7% | -281.5% | -539.3% | -139.3% | -263.7% | |
| 46.9% | 22.2% | 15.5% | 11.3% | 17.9% | 15.6% | 15.0% | 17.7% | 23.0% | 14.5% | 33.6% | 8.1% | 14.9% | |
| 32.4% | 24.4% | 16.5% | 10.0% | 15.9% | 13.2% | 16.8% | 23.8% | 38.3% | 26.5% | 69.1% | 15.3% | 27.7% | |
| -146.6% | 69.9% | -207.3% | -73.2% | 29.1% | -12.6% | -148.7% | -30.9% | -105.5% | -136.5% | 5.3% | -65.7% | -81.8% | |
| 24.7% | 18.3% | 16.4% | 4.2% | 7.4% | 3.1% | 5.0% | 2.6% | 5.8% | 11.2% | 7.9% | 3.3% | 6.2% | |
| -24.7% | 152.3% | -398.5% | -4.2% | 434.9% | -64.7% | -5.0% | -2.6% | -5.8% | -11.2% | -7.9% | -3.3% | -6.2% | |
| – | – | – | – | -11.8% | -5.9% | -12.5% | -7.7% | -15.2% | -12.9% | -14.7% | -7.0% | -10.6% | |
| -20.5% | -33.3% | -9.4% | -4.5% | -11.8% | 1,658.5% | -11.1% | -7.7% | -15.2% | -12.7% | -14.7% | 554.7% | 259.3% | |
| -584.7% | -49.5% | -746.3% | -106.9% | 271.4% | 1,393.2% | -376.1% | -331.4% | -441.9% | -312.5% | -548.0% | 397.5% | -18.0% | |
| -572.8% | -180.4% | -356.5% | -103.5% | -154.6% | -220.1% | -354.5% | -301.3% | -425.5% | -292.7% | -547.3% | -142.6% | -269.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.